Name: | Anakinra |
---|---|
Name (isomeric): | DB00026 |
Drug Type: | biotech |
Description: | A synthetic form of native human IL-1Ra that has an additional methionine residue at its amino terminus. |
Synonyms: |
IL-1ra; IL1 inhibitor; IL-1RN; Interleukin-1 receptor antagonist protein precursor; IRAP; ICIL-1RA
|
Brand: | Kineret (Amgen Inc) |
Category: | Immunomodulatory Agents, Antirheumatic Agents |
CAS number: | 143090-92-0 |
Indication: | For the treatment of adult rheumatoid arthritis. |
---|---|
Pharmacology: |
Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including infl...
show more » |
Mechanism of Action: | Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption. |
Absorption: | Anakinra had an absolute bioavailability of 95% for healthy adults (n = 11) after a 70 mg subcutaneous bolus injection. |
Biotransformation: | renal |
Half Life: | 4-6 hrs |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|